Level C· Early human research exploring benefitsCase Report / SeriesPubMed

Barraquer-Simons syndrome: a unique patient's perspective on diagnosis, disease progression and recontouring treatment.

Heidemann LN., Thomsen JB., Sørensen JA.

Case Report / Series on Face & Skin, Systemic / IV, published in BMJ Case Rep (2016) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
BMJ Case Rep (2016)
Country
England
Reported sample size
—
Source database
PubMed
PMID
27402657
DOI
10.1136/bcr-2016-216134

Abstract (original English)

This case report describes a female patient diagnosed with Barraquer-Simons syndrome, a rare form of acquired partial lipodystrophy characterised by symmetrical loss of adipose tissue from face, neck, upper extremities and the trunk with onset in early childhood. Initial symptoms were seen at the age of 8 years. Our patient did not show signs of renal impairment and this may be associated with the syndrome. Treatment of lipoatrophy in these patients is limited to cosmetic restoration, and autologous fat grafting has shown sustained positive effects with no or very little loss of volume at follow-ups. Furthermore, the treatment has resulted in considerable improvements in her quality of life and daily functioning. She has not experienced any adverse effects. Accurate and early diagnosis is important, and clinicians should consider early intervention for these patients. Autologous fat grafting is recommended as a safe procedure.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Activities of Daily LivingAdipose TissueAdultDisease ProgressionFemaleHumansLipodystrophyQuality of LifeSyndromeTissue Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research